Citations

Showing 10 of 108083 citations.

Delayed motor weakness following peripheral nerve schwannoma resection: illustrative cases
Spinner, Robert J. , Singh, Rohin

Mayo Clinic

Journal of Neurosurgery: Case Lessons | January 2, 2023 | Volume: 5 | Issue: 1 | Pages: No page available

10.3171/case22510 | PMID 36593673 Get It

BACKGROUND Delayed facial palsy (DFP) after vestibular schwannoma resection is a well-documented, yet poorly understood condition. The exact pathophysiological mechanisms of DFP are unknown, although diminished intraoperative nerve response has been shown to be a prognostic factor. To date, no such condition has been described in regard to peripheral nerve schwannomas. OBSERVATIONS Here the authors present the first reported cases of delayed motor weakness (DMW) after peripheral schwannoma resection of the ulnar nerve at the elbow and peroneal nerve in the popliteal fossa. Both patients presented with a mass lesion and radiating paresthesias and had normal motor function preoperatively. Immediately after surgical resection, the patients had full strength. Within 24 hours, both patients exhibited marked weakness that gradually resolved over the course of several weeks. LESSONS DMW after peripheral schwannoma resection is a rare condition likely akin to delayed facial nerve palsy after VS resection. The mechanism of this phenomenon remains unknown, although symptoms appear to self-resolve with time. A better understanding of the processes driving this condition may allow for therapies that can expedite and improve long-term outcomes.
Novel dendritic cell (DC)-stimulating antibody, B7-DCXAb, effectively downregulates allergen-specific IgE, IgG1, Th2 cytokines, and allergic inflammation (36.13)
Pease, Larry R. , Checkel, James L., Iijima, Koji, Radhakrishnan, Suresh , Keulen, Virginia P. Van , McClimon, Brad J., Plager, Douglas A., Kobayashi, Takao , Kita, Hirohito

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 182 | Issue: 1_Supplement | Pages: 36.13-36.13

10.4049/jimmunol.182.supp.36.13 Get It

Abstract We investigated whether human IgM antibody, B7-DCXAb, which binds to B7-DC and enhances DCs' antigen uptake and retention, migration, and cytokine production, improves the efficacy of allergen immunotherapy. Mice were sensitized by intraperitoneal injection of OVA or house dust mite (HDM) antigens plus alum and then treated by intravenous B7-DCXAb injection intranasal or sublingual administration of antigen. OVA-sensitized mice developed anti-OVA IgE and IgG1, Th2-type splenocyte responses to OVA; marked airway eosinophilic inflammation was observed after intranasal OVA challenge. When these mice were treated by intravenous B7-DCXAb plus intranasal OVA, anti-OVA IgE and IgG1 decreased by 75~95% within 1 week; this decrease persisted for >8 weeks. Anti-OVA IgG2a decreased transiently. Splenocyte production of IL-4, IL-5, and IL-13 in response to OVA was abolished; no increases in IFN-g or IL-17 were noted. In OVA-challenged mice, airway eosinophilia and lung levels of IL-4, IL-5 and IL-13 were reduced by >90%. Immunotherapeutic effects were also observed with intravenous B7-DCXAb plus sublingual OVA, but not with intravenous B7-DCXAb alone. Furthermore, HDM-sensitized mice were treated successfully by intravenous B7-DCXAb plus intranasal HDM. B7-DCXAb injection plus mucosal administration of antigen effectively treats allergic responses and may provide novel strategy for allergen immunotherapy.
The immune function of aging T cells (35.6)
Mirza, Noweeda, Lustgarten, Joseph, Hoelzinger, Dominique B. , Dominguez, Ana Lucía

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 182 | Issue: Supplement_1 | Pages: 35.6-35.6

10.4049/jimmunol.182.supp.35.6 Get It

Abstract Age related changes compromise T cell mediated immunity. Previous findings suggest that the aged immune T cell repertoire can be exploited to mount effective anti-tumor responses to immunogenic tumors. However, antitumor immune responses against tumor self-antigens are significantly dysregulated in the old; hence, the salient differences in the biology and function of T cells between young and old, should be elucidated. These differences fall into three categories: (i) there are lower surface levels of T cell receptor (TCR) on old CD4 and CD8 T cells, (ii) the TCR complex is cycled differently in aged T cells and (iii) the TCR complex may be disassociated in older animals. Therefore these preliminary findings support the hypothesis that aging causes a decline in T cell function. Data analyses from a T cell activation time-course microarray study show that there are large differences in the gene expression profiles of old and young naive cells in CD4 (2022 genes) and CD8 (3666 genes) subsets. These differing genetic signatures point to potentially dysregulated proteins in the old immune system. Further investigation of selected gene products using appropriate mouse models, may provide valuable preclinical information with significant therapeutic potential which could have the opportunity of being translated into clinical trials. This work was sponsored in part by a grant from AFAR.
Constitutive expression of TIGIT defines a population of CD4+ regulatory T cells in Bcell non-Hodgkin lymphoma
Price-Troska, Tammy, Jalali, Shahrzad , Novak, Anne J. , Ansell, Stephen M., Yang, Zhi-Zhang , Kim, Hyo Jin , Villasboas, José C.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 198 | Issue: Supplement_1 | Pages: 155.12-155.12

10.4049/jimmunol.198.supp.155.12 Get It

Abstract T cell Ig and ITIM domain (TIGIT) is an immune checkpoint molecule and its ligation delivers an inhibitory signal to T cells that negatively regulates anti-tumor responses. However, the expression and biological relevance of TIGIT in B-cell non-Hodgkin lymphoma (NHL) is completely unknown. To phenotypically characterize TIGIT+ T cell subsets, we profiled TIGIT-expressing CD4+ and CD8+ T cells from biopsy specimens of B-cell NHL. TIGIT expression was not detectable on T cells from peripheral blood, however, TIGIT is constitutively expressed on CD4+ T cells from biopsy specimens of B-cell NHL with a median of 44.8% (range: 25.9–62.2, n=8) of CD4+ T cells expressing TIGIT. By profiling the CD4+TIGIT+ T cells, we observed that CD25 was highly expressed on intratumoral CD4+TIGIT+ T cells. Intracellular staining revealed that Foxp3 was expressed by intratumoral CD4+TIGIT+ T cells. These intratumoral CD4+TIGIT+ T cells expressed high level of chemokine receptor CCR4 and were absent of IL-7 receptor-α (CD127). Functionally, CD4+TIGIT+ T cells displayed reduced cytokine production, as the number of IFN-γ- and TNF-α-producing cells was lower in the TIGIT+ population than in TIGIT− T cells. While TIGIT expression can be induced by TCR activation, treatment of T cells with IL-2 and TGF-β inhibited TCR-mediated TIGIT induction. Furthermore, lymphoma B cells were involved in TIGIT induction as in vitro depletion of lymphoma B cells altered upregulation of TIGIT on CD4+ T cells in B-cell NHL. Taken together, these results indicated that constitutive expression of TIGIT defines a CD4+ population with similar phenotype to regulatory T cells. Inhibition of TIGIT signaling may be an additional mechanism to prevent T-cell suppression in B-cell NHL
A Feature Extraction Using Probabilistic Neural Network and BTFSC-Net Model with Deep Learning for Brain Tumor Classification
Yadav, Arun Singh , Kumar, Surendra , Karetla, Girija Rani , Cotrina-Aliaga, Juan Carlos , Arias‐Gonzáles, José Luis , Kumar, V. Vinay, Srivastava, Satyajee , Ibrahim, Sufyan , Naik, Nithesh , Singla, Babita , Ibrahim, Sufyan , Naik, Nithesh , Gupta, Reena , Paul, Rahul , Tatkar, Nisha S.

Mayo Clinic

Journal of Imaging | January 2, 2023 | Volume: 9 | Issue: 1 | Pages: 10

10.3390/jimaging9010010 | PMID 36662108 Get It

Background and Objectives: Brain Tumor Fusion-based Segments and Classification-Non-enhancing tumor (BTFSC-Net) is a hybrid system for classifying brain tumors that combine medical image fusion, segmentation, feature extraction, and classification procedures. Materials and Methods: to reduce noise from medical images, the hybrid probabilistic wiener filter (HPWF) is first applied as a preprocessing step. Then, to combine robust edge analysis (REA) properties in magnetic resonance imaging (MRI) and computed tomography (CT) medical images, a fusion network based on deep learning convolutional neural networks (DLCNN) is developed. Here, the brain images’ slopes and borders are detected using REA. To separate the sick region from the color image, adaptive fuzzy c-means integrated k-means (HFCMIK) clustering is then implemented. To extract hybrid features from the fused image, low-level features based on the redundant discrete wavelet transform (RDWT), empirical color features, and texture characteristics based on the gray-level cooccurrence matrix (GLCM) are also used. Finally, to distinguish between benign and malignant tumors, a deep learning probabilistic neural network (DLPNN) is deployed. Results: according to the findings, the suggested BTFSC-Net model performed better than more traditional preprocessing, fusion, segmentation, and classification techniques. Additionally, 99.21% segmentation accuracy and 99.46% classification accuracy were reached using the proposed BTFSC-Net model. Conclusions: earlier approaches have not performed as well as our presented method for image fusion, segmentation, feature extraction, classification operations, and brain tumor classification. These results illustrate that the designed approach performed more effectively in terms of enhanced quantitative evaluation with better accuracy as well as visual performance.
Thrombosis in multiple myeloma: Risk estimation by induction regimen and association with overall survival
Charalampous, Charalampos , Goel, Utkarsh , Kapoor, Prashant , Binder, Moritz , Dingli, David , Fonder, Amie , Gertz, Morie A. , Gonsalves, Wilson I. , Hayman, Suzanne R. , Hobbs, Miriam, Hwa, Yi L. , Kourelis, Taxiarchis , Lacy, Martha Q. , Warsame, Rahma , Kyle, Robert A. , Kumar, Shaji , Charalampous, Charalampos , Dispenzieri, Angela , Fonder, Amie L, Gertz, Morie A , Gonsalves, Wilson , Hwa, Yi L , Kourelis, Taxiarchis , Leung, Nelson , Warsame, Rahma , Rajkumar, S Vincent , Kumar, Shaji K , Binder, Moritz , Dingli, David , Charalampous, Charalampos , Buadi, Francis K. , Dispenzieri, Angela , Leung, Nelson , Lin, Yi , Rajkumar, S. Vincent

Mayo Clinic

American Journal of Hematology | January 2, 2023 | Volume: 98 | Issue: 3 | Pages: 413-420

10.1002/ajh.26806 | PMID 36588396 Get It

Abstract Lenalidomide‐containing (R) triplet and quadruplet regimens are the standard of care for multiple myeloma (MM) and have been shown to increase the risk of thrombosis. The association between thromboembolism (TE) and survival in the novel multidrug era is not yet delineated. In this study, we evaluated the incidence of TE during the first year of MM diagnosis, its association with the type of induction regimen, and its impact on overall survival. We studied 672 newly diagnosed MM (NDMM) patients who received a triplet or quadruplet lenalidomide‐based induction at the Mayo Clinic, Rochester. TE was diagnosed in 83 patients (12.4%). Of these, 56 (8.3%) had a deep venous thrombosis (DVT), 23 (3.4%) had a pulmonary embolism (PE) with or without the DVT, and 4 (0.6%) patients had a stroke. Carfilzomib‐Rd (KRd) had the highest risk of TE (21.1%, 18/85), followed by quadruplets (11.1%, 5/45), bortezomib‐Rd (9.6%, 51/531), and 0/11 (0%), treated with other lenalidomide‐containing regimens. The difference in TE risk between KRd and the other regimens was statistically significant (OR = 2.6, p < .01). Nine patients developed a TE before being exposed to any treatment. Survival was significantly lower among patients that developed a TE (66 vs. 133 months, p < .01). The association of TE with reduced survival demonstrated in univariate analysis (HR = 2.2, 95% CI = 1.6–3.3) was maintained in the multivariable analysis adjusted for high‐risk interphase fluorescence in situ hybridization (FISH), sex, age, receipt of an upfront transplant, the response at induction, and the International Staging System (ISS) (HR = 2.61, CI = 1.74–3.9). We conclude that TE is an important aspect of MM management, and effective management is especially relevant in the novel treatment era.
DRB1*0402 protects while DRB1*0401 is permissive for inducing collagen-induced arthritis in transgenic mice (130.45)
Behrens, Marshall D., Luthra, Harvinder S., David, Chella S., Taneja, Veena , Griffiths, Marie

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S236-S237

10.4049/jimmunol.178.supp.130.45 Get It

Abstract DRB1*0401 has been associated with predisposition to rheumatoid arthritis while DRB1*0402 is associated with resistance. We have generated transgenic mice lacking endogenous H2-A and E molecules (AEo) but expressing DRB1*0401 or DRB1*0402 molecules. All transgenic mice expressed functional DR molecules which could positively and negatively select various Vβ T cell repertoire profile. Transgenic mice were studied in vivo for induction of arthritis following immunization with type II collagen. DRB1*0401 mice are susceptible to collagen-induced arthritis while DRB1*0402 mice are resistant. Presence of DR4 leads to arthritis predominantly in female mice. CIA susceptible AEo.DQ8 mice have been shown to develop arthritis without a gender bias. However, AEo mice expressing DRB1*0401.DQ8 develop arthritis in female mice with a ratio of 3F:1M, similar to that in humans. DRB1*0402 mice did not show any defect in humoral response though they demonstrated a lower cellular response to CII and an increased activation-induced cell death compared to susceptible mice. In vitro T cell response with superantigen staphylococcal enterotoxin B and Concovalin A showed that DRB1*0402 mice are not defective in generating T cell response. The resistant mice showed an increased cell death in thymus suggesting deletion of autoreactive T cells at thymic level might be one reason for protection. The data suggest that DRB1 polymorphism lead to selection of TCR in thymus thus controlling the selection of autoreactive T cells available in periphery. Thus these transgenic mice may be useful to study the reasons for gender-bias observed in human patients develop therapeutic strategies.
Spontaneous Gluten Dependent Blistering in DQ2 transgenic mice (130.9)
Marietta, Eric, Rashtak, Shadi , Pittelkow, Mark R. , David, Chella S., Murray, Joseph A.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S229-S229

10.4049/jimmunol.178.supp.130.9 Get It

Abstract Background/Aim: Dermatitis Herpetiformis is the autoimmune skin manifestation of celiac disease, and similar to celiac disease, is tightly associated with HLA-DQ2 and HLA-DQ8. Previously we have generated a mouse model of DH using DQ8 transgenic mice on an NOD background. Herein, we describe a similar DH-like blistering disease that spontaneously develops in DQ2 transgenic mice. Methods: Transgenic mice that express DQ2 on a background deficient in endogenous MHC II (Aeo) were raised on a gluten containing (GC) chow or a gluten free chow . Results: When raised and maintained on a gluten containing chow, approximately 15% of these Aeo DQ2 mice spontaneously developed blisters on the ears and tails at about six months of age. Control Aeo mice that were also raised on a gluten containing chow did not develop this blistering disease during their lifetime. Hematoxilyn and eosin staining revealed subepidermal blisters. Immunohistochemistry revealed IgA deposits at the dermal/epidermal junction in perilesional ear tissue. However, when these mice were raised and maintained on a gluten free diet, these mice did not develop blisters. Conclusions: This blistering disease is a gluten dependent disease that has many of the elements typically associated with Dermatitis Herpetiformis, most especially the association with the DQ2 gene.
Chronic low-grade exposure to bacterial superantigens elicits sustained T cell expansion and multiorgan inflammation. Implications for autoimmunity. (130.22)
Rajagopalan, Govindarajan , Smart, Michele, Grande, Joseph P. , David, Chella S.

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S232-S232

10.4049/jimmunol.178.supp.130.22 Get It

Abstract Bacterial superantigens (BSAg) are produced by Staphylococcus aureus and Streptococcus pyogenes. BSAg bind directly to the MHC class II molecules without undergoing any processing and subsequently activate T cells in an antigen non-specific manner by interacting with the TCR Vβ region. BSAg have been implicated primarily in acute diseases such as food poisoning, toxic shock syndrome, etc. Since carrier strains of S. aureus and S. pyogenes can elaborate superantigens, there is a distinct possibility of chronic exposure to low doses of BSAg and it is imperative to study its outcome. As BSAg bind more avidly to human (HLA) than to murine (H-2) MHC class II, we delivered low concentrations (total of 10 μg/mouse) of BSAg to HLA-DR3 [staphylococcal enterotoxin (SE) B] or HLA-DQ8 [streptococcal pyrogenic exotoxin (SPE) A] transgenic mice through subcutaneously implanted miniosmotic pumps for 7 days. Continuous exposure to low concentrations of BSAg resulted in a significant protracted expansion of CD4+ T cells expressing TCR Vβ8 (for SEB); Vβ8 and Vβ14 (for SPEA) with a concomitant decrease in percentage of CD8+ T cells expressing these TCR. T cells bearing TCR Vβ6 showed an inverse correlation (slight decrease in CD4+ and increase in CD8+ compartments with SEB and SPEA). Histological examinations of major organs showed intense perivascular infiltration in lungs, kidneys and liver along with inflammatory infiltrates in the cardiac valvular endothelium in mice bearing pumps delivering BSAg but not PBS. In conclusion, we have shown the immunological outcome of chronic exposure to low levels of BSAg using the HLA class II transgenic mouse model.
A novel H2A−E+ transgenic model susceptible to human but not mouse thyroglobulin in autoimmune thyroiditis: identification of a mouse pathogenic epitope (129.37)
McCormick, Daniel J., David, Chella S., Kong, Yi‐chi M., Brown, Nicholas K. , McCormick, Daniel , Brusić, Vladimir

Mayo Clinic

The Journal of Immunology | January 2, 2023 | Volume: 178 | Issue: 1_Supplement | Pages: S225-S225

10.4049/jimmunol.178.supp.129.37 Get It

Abstract Experimental autoimmune thyroiditis (EAT) is a model for Hashimoto’s thyroiditis which is characterized by mononuclear cell infiltration and follicular destruction. We previously reported on an Eα-transgenic strain (H2A−E+) that is highly susceptible to human (h) thyroglobulin (Tg)-induced EAT, but strongly tolerant to mouse (m)Tg. After mTg and adjuvant, traditional, resistant strains do not develop thyroiditis, nor detectable primed T cell proliferation, but do make anti-mTg Abs. By contrast, this H2Eb+ strain does not even produce mTg Abs. To identify what epitopes in the mouse thyroid hTg-primed, thyroiditogenic T cells recognize to evoke EAT, we first confirmed that hTg-primed cells do not respond to mTg, nor to other thyroid Ags. We next selected the three immunogenic epitopes on hTg known to be processed and presented by H2Eb, as the basis for synthesizing potential mTg epitopes. One 15-mer peptide, mTg409, did prime T cells, elicit Ab, and generate moderate thyroiditis. Thyroiditis incidence was increased after adoptive transfer of in vitro activated, mTg409-primed cells. Moreover, cells primed to hTg410, the corresponding, pathogenic hTg peptide, cross-reacted with mTg409, and vice versa. This mTg autoepitope, identified by using thyroiditogenic hTg epitopes, helps to explain the severe thyroiditis seen in this novel H2E+ transgenic model. (Supported by NIH grant DK45960)